89bio to participate in the h.c. wainwright 8th annual mash investor conference

San francisco, sept. 30, 2024 (globe newswire) -- 89bio, inc. (the “company” or “89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the company's management will participate in a fireside chat and one-on-one investor meetings at the h.c. wainwright 8th annual mash investor conference on monday, october 7, 2024 at 11:30 am et.
ETNB Ratings Summary
ETNB Quant Ranking